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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYUnderstanding themechanisms of cancer initiation will help to prevent andmanage the disease. At present, the role of the breast micro-
environment in transformation remains unknown. As BMP2 and BMP4 are important regulators of stem cells and their niches in many
tissues, we investigated their function in early phases of breast cancer. BMP2 production by tumor microenvironment appeared to be
specifically upregulated in luminal tumors. Chronic exposure of immature humanmammary epithelial cells to highBMP2 levels initiated
transformation toward a luminal tumor-like phenotype, mediated by the receptor BMPR1B. Under physiological conditions, BMP2
controlled themaintenance and differentiation of early luminal progenitors, while BMP4 acted on stem cells/myoepithelial progenitors.
Our data also suggest that microenvironment-induced overexpression of BMP2 may result from carcinogenic exposure. We reveal a role
for BMP2 and the breast microenvironment in the initiation of stem cell transformation, thus providing insight into the etiology of
luminal breast cancer.INTRODUCTION
Understanding the cell of origin of cancer is pivotal for a
better prevention and more efficient cure of the disease.
Some examples of cancers arising from the transformation
of stem cells have been shown, but inmost cases, the cell of
origin remains unknown. In healthy tissue, the microenvi-
ronment (niche) governs the fate of stem cells by balancing
their self-renewal and differentiation through the regu-
lation of the availability of soluble molecules, cell-cell
contact, cell-matrix interactions, and physical constraints
(Maguer-Satta, 2011). Increasing evidence indicates that
the microenvironment plays an active role in cancer, such
as alterations of mesenchymal stem cells that promote
the proliferation and dissemination of cancer cells (McLean
et al., 2011). However, the role of themicroenvironment in
the initial steps of cell transformation remains unexplored.
The niche can affect normal stem cells and their malig-
nant counterparts through soluble signals that create a
carcinogenic microenvironment (Li et al., 2012). Among
the soluble signals, inflammatory cytokines such as inter-
leukin-6 (IL-6) play an important role in cancer (Iliopoulos
et al., 2011; Vendramini-Costa and Carvalho, 2012). Ab-
normalities in bone morphogenetic protein (BMP) expres-Stem Cellsion and their signaling pathway have also been reported
in many systems (Davies et al., 2008; Thawani et al.,
2010). BMP proteins are soluble members of the transform-
ing growth factor b (TGF-b) superfamily that govern stem
cell regulation in embryonic development, hematopoietic,
neural, and epithelial systems, including the mammary
gland (Alarmo et al., 2013; Forsman et al., 2013; Jeanpierre
et al., 2008; Rendl et al., 2008). BMP signaling affects the
stem cell niche both directly and indirectly (Zhang et al.,
2003). Within this family, BMP2 and BMP4 are important
regulators of both normal and cancer stem cells (Laperrou-
saz et al., 2013; Sagorny et al., 2012). In breast cancer, BMP2
and BMP4 have both protumor and antitumor functions
(Balboni et al., 2013; Clement et al., 2005), but alterations
of BMP receptors and their intracellular signal transducers
SMAD1/5/8 clearly contribute to cancer progression and
metastasis (Helms et al., 2005; Katsuno et al., 2008). Multi-
ple abnormalities of BMP signaling have been reported
in breast cancer, but available data only document a role
in advanced disease, while effects on early transforming
events remain to be identified.
Using primary tissue, we have analyzed the expression
levels of BMP molecules in the breast microenvironment
and signaling in normal mammary cells and tumors. WeReports j Vol. 4 j 239–254 j February 10, 2015 j ª2015 The Authors 239
identified BMP2 as an important factor of the stem cell
niche that regulates the luminal differentiation of mam-
mary progenitors. Using a cell line model of immature hu-
man mammary epithelial cells, we investigated the impact
of continuous deregulation of BMP levels on cell trans-
formation. Our data evidence that some luminal breast tu-
mors likely arose as a result of an amplified response of
mammary stem cells to normal BMP2- and BMPR1B-medi-
ated signaling. We provide evidence that the alteration of
the microenvironment upon exposure to common carcin-
ogens increases BMP2 production. We uncover a role for
the BMP pathway in the origin of luminal breast cancer.RESULTS
Luminal Breast Tumors Exhibit Altered BMP2 Levels
Provided by Tumor Microenvironment
We compared concentrations of BMP2 and BMP4 in the su-
pernatant obtained from fresh normal, luminal, or basal tu-
mor tissue. While no difference was observed for BMP4,
BMP2 levels were significantly increased in luminal tumors
compared with normal tissue or basal tumors (Figure 1A).
By analyzing gene expression of the BMPs pathway (Fig-
ure S1A available online) using data from 161 primary
breast tumors and three normal samples (Farmer et al.,
2005), we found significant lower levels of BMP2 transcript
in luminal tumor cells compared to normal samples (Fig-
ure 1B). BMP2 expression in normal and tumor tissue was
examined by immunohistochemical (IHC) staining of
breast tissue obtained fromhealthy donors or normal tissue
area of luminal or basal tumor sections as well as analysis of
a tumormicroarray (TMA) of 440 tumors. In normal breast,
BMP2 was mainly expressed by myo/basal epithelial cells
and endothelial cells constituting vessels (Figure 1C). IHC
analysis of tumor sections revealed only weak global stain-
ing of both basal and luminal tumors with almost no signal
in epithelial tumor cells (Figure 1D). TMA IHC showed no
significant differences in the percentage of BMP2-positive
(50%) tumors with respect to tumor subtype (Figure 1E),
and for both tumor subtypes, less than 20% percent of tu-
mor cells stained positive (Figure 1F). It suggests that high
levels of BMP2 detected in tumor supernatants are not pro-
duced by tumor cells themselves. To identify BMP-secreting
cells, we analyzed BMP2 and BMP4 expression in different
fractions of normal mammary tissue enriched in epithelial
organoids, fibroblasts, adipocytes, and a variable mix of
epithelial cells, hematopoietic cells, and other stromal cells
(Stingl et al., 2005) (Figure S1B). Unlike BMP4, BMP2-
expression was comparable across all fractions (Figure 2A).
Flow cytometry revealed enrichment of mesenchymal,
myoepithelial, and endothelial cells in the stromal and
hematopoietic fraction (Figure S1C). Using IHC staining240 Stem Cell Reports j Vol. 4 j 239–254 j February 10, 2015 j ª2015 The Aof serial sections of normal tissue for BMP2, pan-keratin,
smooth muscle actin (SMA), and CD45, we identified
epithelial cells (pan-keratin-positive), fibroblasts and other
stromal cells (SMA-positive) as BMP2-secreting cells, while
CD45-positive leukocytes rarely stained positive (Fig-
ure 2B). Based on cell morphology, the BMP2-positive cells
detected in luminal tumors were classified as stromal cells
and endothelial cells disseminated within the luminal tu-
mor (Figure 2C). Accordingly, TMA quantification showed
a consistent increase in the percentage of BMP2-positive
vessels (2.1-fold) and stroma (1.5-fold) in luminal over
basal tumors (Figure 2D). Finally, IHC analysis of serial
luminal tumor sections confirmed that keratin-positive/
SMA-negative epithelial tumor cells stained negative while
CD31-positive endothelial cells clearly stained for BMP2
(Figures 2C and 2E). These results are consistent with the
quantification of soluble BMP2 by ELISA (Figure 1A) and
transcript analysis (Figures 2A and S1C), and identify endo-
thelial cells of vessels as the principal source of BMP2 and to
a lesser extent, fibroblasts, and other stromal cells.While in
normal tissue, BMP2 is predominantly produced by normal
myoepithelial cells, fibroblasts, stromal cells, and some rare
luminal epithelial cells, in luminal tumors, increased BMP2
levels are produced by the microenvironment alone.
Deregulation of the Intrinsic BMP Pathway in
Luminal Breast Tumors
We analyzed Affymetrix data for a correlation of BMP
pathway gene expression with breast cancer markers
(Farmer et al., 2005). Breast cancer subtypes were classified
as indicated in methods by estrogen receptor alpha (ESR1)
and forkhead box transcription factor A1 (FOXA1) expres-
sion. Expression of FOXC1, a biomarker of aggressiveness
and basal-like subtype, is inversely correlated with ESR1,
GATA3, or FOXA1 (Figure 3A). FOXA1-positive luminal tu-
mors expressed high KERATIN 18 and low KERATIN 14 and
5, as shown in both Affymetrix data and freshly isolated
breast tumors (Figures 3B and S2E). The most striking
BMP pathway alteration was a high expression of the
BMP receptor type 1B (BMPR1B) in the majority of luminal
tumors, while BMPR1A and BMPR2 receptors were ex-
pressed in a subtype-independent manner (Figure 3C).
Expression of BMP-regulated SMAD5 and target genes
RUNX1 and RUNX2 was increased in FOXA1-positive tu-
mors, while SMAD1/6/7/9, ID1/2/3, and RUNX3 levels ap-
peared either unchanged or repressed (Figures 3C and S2A).
We separated by flow cytometry luminal (EpCAM+) and
immature/myoepithelial (CD10+) cells of primary normal
and tumor tissue (Bachelard-Cascales et al., 2010; Keller
et al., 2012). In the normal breast, all key elements of the
BMP pathway were expressed (Figure 3D), but the CD10+
subpopulation was enriched for BMP2, BMP4, BMPR1B,
and the negative regulators SMAD6 and NOGGIN. BMPR1Authors
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D
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B Figure 1. Luminal Breast Tumors Exhibit
Altered BMP2 Expression
(A) ELISA quantification of BMP4 and BMP2
in supernatant obtained from normal (n = 6),
basal tumor (n = 5), or luminal tumor (n = 17)
samples. Data represent the ratio to normal
± SEM, **p < 0.001.
(B) Microarray analysis of BMP2 versus FOXA1
expression. White diamonds, normal sam-
ples; red squares, basal tumors; dark blue
circles, luminal tumors; light blue circles,
apocrine tumors. Pearson’s values of statis-
tical testing R2 and p value are presented.
(C and D) IHC analysis of BMP2 expression in
(C) normal breast tissue or (D) tumor area.
Arrows indicate the following cells: my-
oepithelial/basal (Myo/Bas), luminal epi-
thelial (Lu), tumor cells (Tum), stromal/
fibroblast (Stro), or endothelial vessel (Ve).
Scale bar represents 20 mm.
(E and F) Quantification of BMP2 IHC stain-
ing of 350 luminal and 30 basal tumors. (E)
Percentage of tumors that stained positive
for BMP2. (F) Percentage of BMP2-positive
tumor area.expression was overall increased in tumor compared with
normal breast tissue (Figure 3E). In contrast, BMPR1B
expression was higher in luminal than in basal tumors,
and tumors expressed higher levels of BMPR1B in theStem CellCD10+ than in the EpCAM+ fraction, while subpopulations
of the normal tissue displayed comparable levels of
BMPR1B. Flow cytometry analysis confirmed these find-
ings, suggesting that in luminal tumors, BMPR1B wasReports j Vol. 4 j 239–254 j February 10, 2015 j ª2015 The Authors 241
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Figure 2. BMP2 Is Produced by Stromal and Endothelial Cells in Luminal Tumors
(A) qPCR analysis of BMP2 and BMP4 expression in indicated cellular fractions from normal human mammoplasty and adipose tissue
samples. Data represent the mean ratio to reference ± SEM, n = 5 independent experiments.
(B, C, and E) IHC staining for BMP2, epithelial (Pan Keratin), SMA, endothelial (CD31), and pan leukocyte (CD45-pan Leu) of serial sections
of the same luminal tumor. (B) Normal peritumoral tissue. (C and E) Tumor tissue. Arrows indicate the following cells: myoepithelial/basal
(Myo/Bas), luminal epithelial (Lu), tumor cells (Tum), leukocytes (Leuco), stromal/fibroblast (Stro), or endothelial (Ve). Scale bar rep-
resents 20 mm.
(D) Quantification of BMP2 IHC staining of 350 luminal and 30 basal tumors. Data are presented as a percentage of BMP2-positive vessels or
stromal cells for each subtype.
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predominantly expressed on the surface of immature/my-
oepithelial CD10+ cells but not EpCAM+ luminal cells (Fig-
ures S2B and S2C). IHC staining for BMPR1B and CD10
further showed that no significant staining is measured
for CD10 (Figure S2D)while 93%of luminal tumors stained
positive for BMPR1B compared with 73% of basal tumors
(Figure 3F). On average, a higher percentage of tumor
area stained positive in luminal tumors (Figure 3G), but
the staining intensity varied between different tumor
samples and cell types (Figure 3H). Higher magnification
identified heterogenous location of BMPR1B staining
predominantly in normal luminal cells and rare inmyoepi-
thelial/basal cells while tumor cells strongly expressed
BMPR1B but mostly confined to the cytoplasm (Figures
3H and 3I). Our data indicate that luminal breast tumors,
unlike basal tumors, are characterized by increased expres-
sion of BMPR1B.
BMP2 Initiates Malignant Transformation of
Mammary Epithelial Cells
Our data indicate that luminal breast tumors are character-
ized by mammary epithelial cells expressing a high level of
BMPR1B and exposed to elevated concentrations of BMP2.
We then used the basal MCF10A cell line to evaluate
whether chronic exposure of mammary epithelial stem
cells to BMP2 could be involved in their transformation.
TheMCF10A cell line (nonmalignant fibrocysticmammary
tissue, p16/CDKN2A deletion,MYC amplification) (Kadota
et al., 2010) is considered as a model for immature mam-
mary epithelial cells that differentiate in 3D culture (3D ter-
minal ductal lobular unit [TDLU] assay) (Debnath et al.,
2003; Neve et al., 2006). Used as a preneoplastic model,
MCF10A cells form colonies in soft agar and tumors in
mice after oncogenic events (Pires et al., 2013) favored by
IL-6 (Van Huffel et al., 2011). MCF10A cells were exposed
to long-term BMP2 or BMP4 treatment with or without
IL-6 and assayed weekly for their tumorigenic properties
in the absence of cytokines (Figure 4A). BMP4 and IL-6
alone or in combination had no effect, while BMP2 led to
the formation of soft agar colonies (Figure 4B). The size of
BMP2-induced colonies was not increased in the presence
of IL-6 (Figures 4C and 4D). We analyzed the expression
of classic luminal genes, KERATIN 18, ESR1, GATA3, and
FOXA1 (Figures 3A and 3B). IL-6 or BMP2 alone had no
obvious effect following 10weeks of continuous treatment,
while combined treatment led to an induction of ESR1,
FOXA1, and BMPR1B (Figures 4F and S3A). No change
was observed in BMPR1A, BMPR2, KERATIN 5, and 14
expression and immunofluorescent staining confirmed
an increased KERATIN 18 expression (Figures 4E, 4F, S3A,
and S3B). This molecular profile resembled that of epithe-
lial cells isolated from primary luminal but not of basal-
like tumors (Figures 4G and S3A). As expected, we observedStem Cella coexpression of ESR1, FOXA1, and GATA3 (a well-known
regulator of luminal differentiation; Kouros-Mehr et al.,
2006) characteristic to luminal tumors (Figures 3A and
4H). Accordingly, our model reliably reproduced this
phenotype as time course analysis showed that BMP2 but
not by IL-6-induced GATA3 (Figure 4I) while rapidly and
progressively decreased FOXC1 (Figures 3A and 4J) expres-
sion. Conversely, FOXA1 upregulation occurred later (Fig-
ure 4K), suggesting that it constituted a secondary event
not directly caused by BMP2. Therefore, upon chronic
BMP2 exposure, a progressive switch of the FOXA1/
FOXC1 ratio in favor of FOXA1 occurred, ultimately result-
ing in a luminal tumor phenotype and confirmed by the ca-
pacity of cells to respond to estrogen signaling (Figures S3C
and S3D). Our data indicate a role for BMP2 in controlling
GATA3 and the FOXA1/FOXC1 balance during the initia-
tion of luminal tumors. In summary, we show that pro-
longed exposure to high BMP2 levels initiate immature
mammary epithelial cells transformation, resulting in a
luminal phenotype.
BMP2-Mediated Transformation Involves BMPR1B
We next followed BMPR1B expression over time and
observed that it gradually increased upon prolonged
BMP2 treatment (Figure 5A). The enrichment in
BMPR1B-expressing cells was confirmed by flow cytomet-
ric analysis that showed an increase of 18% in membrane
protein expression at 10 weeks, while BMPR1A expression
remained unchanged (Figure 5B). BMPR1B induction
(29%) was reproduced by intrinsic lentiviral-based over-
expression of BMP2 in MCF10A cells (Figure 5C). This
suggests that BMP2/IL-6 enriched in immature cells ac-
cording to CD10-BMPR1B staining observed in both
normal and luminal tumors (Figures 3D, 3F, S2C, and
S2D) and further sustained by the increased ability of
treated MCF10A to form ducts and lobules in the TDLU
assay (Figure S4A). When MCF10A cells were purified
based on BMPR1B expression and continuously exposed
for only 4 weeks to BMP2 with or without IL-6, treated
BMPR1B-negative cells did not form colonies (Figure 5D),
while BMPR1B-postive cells formed colonies upon BMP2/
IL-6 treatment (but not by IL-6 alone) at a rate 3.5 times
higher (4 versus 14 weeks) than that of unsorted cells (Fig-
ures 4B–4D and 5D). To confirm that the observed effect
was BMPR1B specific, we silenced its expression in puri-
fied BMPR1B-MCF10A cells (>99% purity) using a short
hairpin RNA (shRNA) lentivirus directed against BMPR1B
(Figure S4B). shControl and shBMPR1B cells were treated
with BMP2/IL-6 and assayed for colonies in soft agar.
shControl cells behaved like their nontransduced counter-
parts at 4 weeks of treatment (Figures 5D and 5E). In
contrast, knockdown of BMPR1B decreased colony forma-
tion 5-fold (Figure 5E).Reports j Vol. 4 j 239–254 j February 10, 2015 j ª2015 The Authors 243
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Tumorigenicity of MCF10A cells expressing shControl or
shBMPR1B constructs was tested by orthotopic injection
into nude mice following 6 weeks of BMP2/IL-6 treatment.
Tumor growth was monitored for 6 weeks prior to harvest,
paraffin inclusion, and hematoxylin and eosin (H&E)
staining. shControl cells engrafted with a higher frequency
comparedwith shBMPR1B cells, and the average tumor size
was significantly reduced in BMPR1B knockdown cells (Fig-
ures 5F and 5G). Tumor growth over time clearly showed
the loss of transforming effect upon BMPR1B knockdown
(Figure 5H). H&E staining of tumor sections showed that
cells expressing BMPR1B induced the formation of an orga-
nized network of blood vessels containing red blood cells,
which were surrounded by clusters of human cells that
proliferated and formed abnormally large structures (Fig-
ure 5I). In contrast, BMPR1B knockdown cells were spread
out, proliferated significantly less, and did not induce
angiogenesis. Our data indicate that BMP2/IL-6-induced
transformation enables MCF10A cells to engraft and pro-
liferate and to form premalignant lesions in a BMPR1B-
dependent manner. These results confirmed the involve-
ment of BMPR1B in BMP2-mediated transformation of
epithelial cells and further suggest that luminal tumors
may originate in immature mammary epithelial cells.
BMP2 Sustains and Expands Luminal Progenitors and
Is Induced by Carcinogens
While our data revealed an effect on luminal cell transfor-
mation exclusive to BMP2, normal stem/progenitor cells
expressed most elements of the BMP signaling and are
exposed to soluble BMP2 and BMP4 both present in adult
healthy human breast tissue. Epithelial cells from normal
tissue were enriched for immature cells by several passages
inmammosphere culture and treated 7 days by BMPs in the
absence of serum (Figure 6A). BMP2 or BMP4 decreased
cellular proliferation 2-fold without any evidence of
toxicity (Figures 6B, 6C, S5D, and S5E). To explore effects
on stem cells, we treated cells in the epithelial commonFigure 3. BMP2 Cooperates with IL-6 to Initiate Mammary Epithe
(A–C) Microarray analysis of normal and tumor samples for the expres
KRT18; (C) BMPR1A/1B/2, SMAD1/5/9, and target genes ID1/2/3 and
dark blue circles, luminal; light blue circles, apocrine tumors. Pearso
(D) Single cells derived from normal mammoplasties were sorted for CD
elements. The expression is represented as the mean ratio to referen
(E) qPCR analysis of CD10+ and EpCAM+ subpopulations from normal tis
BMPR1A and BMPR1B. Data represent the mean ratio to reference ±
periments.
(F and G) Quantification of BMPR1B IHC staining of 350 luminal and
BMR1B. (G) Percentage of BMPR1B-positive tumor area for each tumo
(H) IHC BMPR1B staining of mammoplasty tissue from two different h
indicate luminal (Lu) and myoepithelial (Myo/Bas) cells. Scale bar re
(I) IHC BMPR1B staining of the same section of luminal tumor 1. (Lef
luminal (Lu) and myoepithelial (Myo/Bas) cells. Scale bar represents
Stem Cellprogenitor-derived colony (ECP-DC) assay (Figures 6A
and S5A; Bachelard-Cascales et al., 2012) and observed
with either BMP a decreased number of all types of derived
progenitors; however, results were not statistical significant
(Figure 6D). To evaluate whether this decrease in ECP-DC
was due to a response of the sphere-forming compartment,
sorted CD49f+CD10+EpCAM cells (100 cells/well) were
treated 1 week in mammospheres assay (Figure 6E) and
showed a significantly reduced sphere-forming ability of
cells in response to BMP4 than to BMP2 (Figure 6F). Subse-
quent seeding of the obtained single-sphere in epithelial
colony-forming cell (E-CFC) assay revealed that only
BMP2 significantly increased colony frequency (Figure 6G).
To assess direct effect on committed progenitors, sphere-
enriched immature cells were treated within the E-CFC
assay. BMP4 treatment decreased all types of colonies
(distinguished as described in the Supplemental Experi-
mental Procedures and Figures S5B and S5C), while BMP2
reduced the number of mixed and myoepithelial colonies,
but increased early and maintained late luminal progeni-
tors (Figure 6H). Together with the increase in the E-CFC
frequency (Figure 6G), it identifies BMP2 as a luminal
lineage commitment factor. This was confirmed by
treating sorted CD49f+CD10+EpCAM immature cells or
CD49f+CD10EpCAM+ purified committed luminal pro-
genitors. CD10-cells treated only in E-CFC assay (not dur-
ing sphere-forming steps to exclude BMP-dependent
effects on lineage commitment) showed that BMP4 and
BMP2 maintained mixed colonies and decreased the num-
ber of committed progenitor-derived colonies of both line-
ages (Figure 6I). It indicates that several days of pre-expo-
sure of immature cells to BMP2 is required to significantly
increase luminal progenitors. Furthermore, BMP2 consti-
tutes a growth factor for EpCAM-committed luminal pro-
genitors, as increasing their numbers of derived early
luminal CFCs (Lu-CFCs) and maintaining their late Lu-
CFC content (Figure 6J). Therefore, in normal breast,
BMP2 and BMP4 play different roles, with BMP4 thatlial Cell Transformation
sion of FOXA1 versus (A) FOXC1, ESR1 or GATA3; (B) KRT5, KRT14, or
RUNX1/2/3. White diamonds, normal samples; red squares, basal;
n’s values of statistical testing R2 and p value are presented.
10 and EpCAM, and qPCR analysis was performed for BMP signaling
ce ± SEM, n = 8.
sue (white bars), luminal (blue bars) and basal (red bars) tumors for
SEM, n = 3. (D and E) n indicates the number of independent ex-
30 basal tumors. (F) Percentage of tumors that stained positive for
r. Solid bars represent median values.
ealthy donors and luminal tumor tissue from two patients. Arrows
presents 20 mm.
t) Normal peritumoral tissue. (Right) Tumor tissue. Arrows indicate
20 mm.
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inhibit proliferation and differentiation of immature cells
and BMP2 that promote engagement and expansion of
luminal progenitors. These finding are in line with a spe-
cific role for BMP2 in the emergence of luminal tumors.
To identify potential causes of deregulated BMP2 produc-
tion, we tested the effect of radiation, shown to induce
BMP2 in stromal cells (Sun et al., 2012) and important envi-
ronmental pollutants involved in breast tumorigenesis, Bi-
sphenol A(BPA), an estrogen mimetic, Bisphenol S (BPS), a
BPA substitute with lower estrogen-receptor binding capac-
ity, and Benzo[a]pyrene (BaP, an aromatic hydrocarbon)
(Rundle et al., 2000; Weber Lozada and Keri, 2011). Cells
isolated from mammoplasty or peripheral adipose tissue
(Figure S1A) were precultured 2 days prior to irradiation
or 5-day treatment with BPA, BPS, or BaP. BMP2 quantifica-
tion in culture supernatants showed no significant effects
of BaP on any cell subtype as well as unaffected adipose tis-
sue-derived cells (Figure 7A). In contrast, breast fibroblasts
producedmore de novo BMP2 upon BPA (3.6-fold increase)
and BPS (2.8-fold) exposure or irradiation (2.7-fold) than
the mixed breast stroma fraction treated with BPA (3.7-
fold), BPS (1.9-fold), or radiation (3.4-fold). This is consis-
tent with a BMP2 production in luminal tumors by endo-
thelial and stromal cells (Figures 2C–2E). Finally, fibroblast
of patients with a breast cancer history are more prone
to produce BMP2 in response to BPA treatment (78%
increased BMP2 mRNA expression) as compared with sam-
ples derived fromhealthy donor tissue (Figure 7B). Secreted
BMP2 protein was found in 33% of supernatants of BPA-
treated cells from cancer patients and only in 10% of
stroma from healthy donors (Figure 7C). Collectively, our
data indicate that luminal tumors may arise from a carcin-
ogen-perturbed BMP2 production by the microenviron-
ment of mammary stem or progenitor cells, which in
turn commit to a BMP2-driven luminal lineage and expand
(Figure 7D).Figure 4. BMP2 Cooperates with IL-6 to Initiate Mammary Epithe
(A) Protocol representation: MCF10A cells were cultured for x weeks w
colony formation assays were performed at each passage and colonie
(B) Quantification of soft agar colonies at 14 weeks ± SEM, n = 6.
(C) Colony size corresponding to x weeks of treatment. Data are pres
(D) Bright-field images of soft agar clones after x weeks of BMP2 ± I
(E) Immunofluorescent staining of MCF10A cells for keratin 14 (KRT
BMP2 ± IL-6. Scale bar represents 100 mm.
(F) qPCR analysis of ESR1, FOXA1, BMPR1A, and BMPR1B expression aft
untreated cells ± SEM, n = 6, *p < 0.05. (B, C, and F) n indicates the
(G) qPCR analysis of ESR1, FOXA1, BMPR1, and BMPR1B expression in
data represent the mean ratio to reference pool of mammary primary
(H and J) Microarray analysis of (H) GATA3 versus ESR1 expression i
normal samples (white diamonds), basal (red squares), luminal (dar
values of statistical testing R2 and p values are presented.
(I and K) Time course representative of six independent experiments
BMP2 versus IL-6-treated cells.
Stem CellDISCUSSION
While current data implicate BMPs in late stages of tumor-
igenesis and metastasis, we uncovered here that BMP2
plays a role in very early stages of the transformation of
immature cells.
Abnormally elevated levels of BMP2 were specifically de-
tected in luminal breast tumors but produced by tumor
microenvironment and not by cancer cells themselves as
reported in leukemia (Gerber et al., 2013; Laperrousaz
et al., 2013). Chronic exposure to BMP2 in the presence
of IL-6 promotes the engagement of immature epithelial
cells toward transformation, as shown by anchorage-inde-
pendent growth and in vivo experiments. Consistent with
difficulties engrafting established human breast tumors in
recipient mice (2.5% for luminal versus 30% for nonlumi-
nal tumors) (Cottu et al., 2012), we did not observe large
and aggressive cell outgrowth. Nevertheless, we obtained
a significant and reproducible engraftment of long-term
BMP2-treated-MCF10A cells, and loss of BMPR1B expres-
sion resulted in a decrease in engrafted cells. BMP2-treated
cells displayed a robust luminal tumor-like phenotype, as
confirmed by multiparameter comparison using two inde-
pendent sets of primary tumors and induce and amplify
intrinsic alterations, such as BMPR1B overexpression.
However, the observed in vivo lesions did not yet resemble
human breast carcinoma, suggesting that our model
mimics an early stage of tumor development. Very interest-
ingly, in vivo cells organized close to neovessels that colo-
nized the coinjected matrigel. This was not observed in
the xenografts of cells expressing shBMPR1B, confirming
that BMPR1B was required for transformation and identi-
fying it as the predominant receptor involved in luminal
tumors from the earliest stages to established tumors
despite its contradictory role in breast cancer prognosis
(Bokobza et al., 2009; Helms et al., 2005). This is alsolial Cell Transformation
ith chronic exposure to BMP2 or BMP4 ± IL-6 (10 ng/ml). Soft agar
s were measured and counted after 3 weeks.
ented in mm ± SEM, n = 6.
L-6 treatment. Scale bar represents 200 mm.
14, red) and keratin 18 (KRT18, green) after chronic exposure to
er 10-week BMP2 ± IL-6 treatment. Data represent the mean ratio to
number of independent experiments.
normal (n = 10), luminal (n = 16), and basal (n = 4) tumor samples;
cells ± SEM, *p < 0.05.
n 92 FOXA1-positive tumors. (J) FOXC1 versus GATA3 expression in
k blue circles), and apocrine tumors (light blue circles). Pearson’s
of (I) GATA3 or (J) FOXA1 (upper) and FOXC1 (lower) expression in
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consistent with our demonstration that in chronic phase of
chronic myeloid leukemia the BMP/BMPR1B pathway pro-
vides key proliferation and expansion signals to leukemic
stem cells (Laperrousaz et al., 2013). Aberrant regulation
of the BMP pathway could therefore be a general mecha-
nism in early phases of the transformation of immature
cells.
We showed that the BMPR1B ligands BMP2 andBMP4 are
present in the human normalmammary gland, where they
occupy different functions in the regulation of mammary
stem/progenitor cell fate (Figure 7). BMP2, but not BMP4,
is able to commit cell to luminal differentiation and expan-
sion of the luminal progenitor compartment, like in the
murine mammary gland (Forsman et al., 2013). Interest-
ingly, luminal progenitors have been reported to be poten-
tially more susceptible to oncogenic events (Lim et al.,
2009; Molyneux et al., 2010) due to short telomere length
(Kannan et al., 2013). This might confer a more genetically
unstable feature to these cells, also specific targets of BMP2
biological cell fate control. Our data indicate that binding
of BMP2 to BMPR1B rapidly induces a sustained signaling
involving GATA3 (as in development; Forsman et al.,
2013) and a change of the FOXA1/FOXC1 balance leading
to luminal immature progenitors expansion that further
transformed through a BMPR1B-dependent signaling.
Therefore, it is possible that under BMP2 signal transforma-
tion arises either from a stem/basal cell that first engages to-
ward a luminal progenitor and then proliferates and further
progresses or directly emerges from an already genetically
altered committed luminal progenitor. Based on our
findings, we cannot rule out one of the two hypotheses. Ir-
respective of the impact of BMP2 on luminal lineage
commitment, the IHC analysis of normal and tumor tissue
indicated that tumor cells themselves are the target rather
than the origin of BMP2 overproduction. The transforma-
tion process may therefore either lead to the loss of BMP2
expression in mammary epithelial cells or occur in an
epithelial cell that does not produce BMP2.
We showed that environmental pollutants such as BPA
(Rundle et al., 2000), and its substitutes, BPS or radiationFigure 5. BMPR1B Is Required for the Initiation of Transformatio
(A) Flow cytometry analysis of BMPR1B expression in MCF10A cells o
(B) Flow cytometry analysis of BMPR1A and BMPR1B expression in unt
(purple) cells at 10 weeks.
(C) Flow cytometry analysis of MCF10A cells transduced with a contro
(D and E) Soft agar colonies numbers ± SEM from MCF10A cells exposed
**p < 0.005, using either (D) flow cytometry-sorted BMPR1B+ and BM
with shControl or shBMPR1B lentiviral vector.
(F–I) Xenografts of the indicated number of shControl or shBMPR1B-ex
treatment. Data represent (F) number of successful grafts per number
mice. (H) Time course of tumor growth following injection with 5E+06
and sectioned. Representative images of H&E stained sections are sh
Stem Cell(Sun et al., 2012), are able to shift the balance of secreted
BMP molecules in favor of BMP2. This seems to happen
more frequently in individuals susceptible of developing
breast cancer. Radiation and/or BPA accumulation in the
mammary stem cell niche might contribute to increase
the local concentrations of BMP2 and IL-6, which in turn
may facilitate epithelial cell transformation and progres-
sion. Indeed, IL-6 secretion by stromal cells can be induced
by BPA (Ben Jonathan et al., 2009) and BMP2 (Hyzy et al.,
2013; Zara et al., 2011), suggesting a possible feedback
loop that maintains transforming conditions. This is
consistent with the high BMP2 staining detected in tumor
endothelial cells also involved in increased angiogenesis
(Finkenzeller et al., 2012; Raida et al., 2005), causing a
continuous influx of BMP-laden platelets, thereby sustain-
ing local high concentrations of BMPs (Labelle et al., 2011).
Epithelial stem cells in themammarymicroenvironment
may be exposed to abnormally high levels of BMP2 over a
prolonged period. Simultaneously, epithelial cells, in-
cluding stem cells, may accumulate genetic alterations
that increase their susceptibility to transforming agents,
such as a change in BMPR1B expression. These events
affect both the microenvironment of the niche and the
epithelial stem cells and create the context for malignant
transformation and progression (Figure 7D). In conclusion,
we provide an insight into themechanism of epithelial cell
transformation at early steps of breast cancer development
driven by an alteration of the stem cell niche in response to
environmental factors. We have highlighted the impor-
tance of the BMP2 signaling pathway in luminal differenti-
ation, which may explain the higher incidence of luminal
versus basal tumors.EXPERIMENTAL PROCEDURES
Preparation of Single-Cell Suspensions from Human
Primary Tissue
The culture of human tissue samples was approved by the ethics
board of the Leon Berard Cancer Center, and patients gave
informed consent. Human mammary epithelial and stromal cellsn of MCF10A Cells
ver 9 months of BMP2 or IL-6 chronic exposure.
reated (black) versus BMP2 (red), IL-6 (blue), or BMP2+IL-6-treated
l or BMP2 vector.
4 weeks to BMP2 ± IL-6 of four independent experiments,*p < 0.05,
PR1B cells or (E) BMPR1B+ cells from the same batch transduced
pressing MCF10A cells in nude mice following 6 weeks of BMP2/IL-6
of mice and (G) mean tumor size in mm3 after 6 weeks ± SEM, n = 5
cells. (I) Tumors were harvested after 6 weeks, paraffin embedded,
own. Scale bar represents 60 mm.
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Figure 6. BMP2 and BMP4 Regulate Immature Human Epithelial Mammary Cells
(A) Schematic diagram of the ECP-DC assay to determine the influence of BMP treatment on stem cell content. Primary mammary epithelial
cells were grown under mammosphere culture conditions ± 50 ng/ml BMP2 or BMP4 for 7 days over several passages. Spheres from 1+x
passages were seeded in the ECP-DC assay without BMP treatment.
(B) Proliferation of cells in response to BMP treatment. Number of cells ± SEM, n = 6, *p < 0.05.
(C) Percentage of viable cells ± SEM, n = 6.
(legend continued on next page)
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were prepared from reduction mammoplasty or abdominal lipo-
plasty tissue, as described in the Supplemental Information.
PrimaryMammaryCell Culture and Functional Assays
For mammosphere assays, single primary mammary epithelial
cells were seeded at limiting dilutions (100 cells/ml) on 96-well ul-
tra-low-attachment plates (BD Corning) in serum-free basal mam-
mary epithelial growth medium (Promocell) supplemented with
B27, 4 mg/ml heparin, 20 ng/ml basic fibroblast growth factor
(both Life Technologies) and epithelial growth factor (EGF)
(Sigma). For E-CFC, primary cells were seeded in complete Epi-
cult-Bmedium (STEMCELLTechnologies) (Stingl et al., 2005). Col-
onies were fixed, stained, and counted according to size and
morphological criteria. Early, highly proliferative E-CFCs were
considered to give rise to large colonies and late, slowly prolifer-
ating E-CFC produced small colonies, measured by Ki67 staining
(Figure S5C). Lineage properties of colonies are defined using clas-
sical criteria and based on keratin 14 and keratin 18 staining (Bach-
elard-Cascales et al., 2010). Quantification of E-CFC following
primary mammosphere formation and dissociation reveals the
initial progenitor content that is rapidly exhausted by in vitro cul-
ture. In contrast, performing the E-CFC assay using cells obtained
from sequential spheres (secondary, tertiary, or more in some
cases) allows quantification of epithelial colonies derived from
early common progenitors that have differentiated during pro-
longed culture to generate new progenitors and tested in the
ECP-DC assay (Figure S5A) (Bachelard-Cascales et al., 2012).
Culture of Cell Lines and Functional Assays
MCF10A cells were purchased from the ATCC and cultured accord-
ing to recommendations in phenol red-free Dulbecco’s modified
Eagle’s medium (DMEM)/F-12 nutrient mix supplemented with
5%horse serum (Life), 10 mg/ml insulin, 0.5 mg/ml hydrocortisone,
100 ng/ml cholera toxin, 20 ng/ml EGF (all Sigma), 1% penicillin/
streptomycin (Life Technologies). BMP2 or IL6 were used at a con-
centration of 10 ng/ml for chronic exposure or 50 ng/ml for 48 hr
of treatment in 2% serum. 3D TDLU assays were carried out in
complete medium as described previously (Bachelard-Cascales
et al., 2010).
Quantification of Soluble BMPs
To determine the concentration of secreted BMPs in the microen-
vironment of primary tissue samples, standardized normal and(D) Effect of BMP treatment on ECP-DC formation. Date represent the
mixed ECP-DC colonies derived from secondary spheres ± SEM, n = 3.
(E) Schematic diagram depicting E-CFC assay for the analysis of prog
(F) Sphere formation in presence of 50 ng/ml BMP2/4. The sphere fr
(G) The percentage of sphere-derived cells that form colonies are sho
black, E-CFC.
(H) E-CFC assay: Cells were treated as shown in (E), and mixed, early/la
Late Myo-CFC, Early Lu-CFC, and Late Lu-CFC) were scored as describe
(I) CD10+ cells were grown as spheres and seeded in the E-CFC assay i
SEM, n = 4.
(J) EpCAM+ cells were directly seeded in the E-CFC assay ± 50 ng/ml BM
F–J) n indicates the number of independent experiments.
Stem Celltumor tissue supernatants were prepared (Faget et al., 2011).
Undigested tissue was mechanically dissociated in DMEM/F-12
nutrient mix, 2% bovine serum albumin (BSA) at a concentration
of 1 ml/0.5 g tissue using scalpels. Supernatants were filtered using
a 40 mMcell strainer and used to quantify soluble BMP2 and BMP4.
Supernatants from cultured cells were concentrated using an Ep-
pendorf Concentrator. ELISA quantifications of BMP2 and BMP4
were performed following the manufacturer’s instructions (Quan-
tikine ELISA Kit; R&D Systems).
Microarray Expression Analysis
Normal and tumor tissue samples were prepared using the same
protocol. Briefly, tissue samples were embedded in Optimal Cut-
ting Temperature. Frozen sections were made. Total RNA were
used for microarray analysis (accession number GSE6861; Gene
ExpressionOmnibus entry) (Farmer et al., 2005). Tumors were clas-
sified into FOXA1-low (basal-like), FOXA1-high/ESR1-high
(luminal), and FOXA1-high/ESR1-low (molecular apocrine), as
described. The cutoffs to define high and low were defined as the
nadirs of the bimodal distributions for the respective genes. Since
the BMPR1B distribution is not bimodal, the cutoff was defined as
themean plus 5 SDs of the values for samples in the negative peak.
The R script to generate the figures is available from the authors.
The CEL files were processed in R with robust multiarray average.
Probesets with a length under 56 nt were removed, and redundant
probesets were removed based on the Entrez gene ID and the SD
across the entire data set.
IHC Staining of Paraffin-Embedded Tissues and Tissue
Microarray
Immunohistochemistry analysis was performed on a tissue micro-
array prepared from 440 breast tumors (Centre Leon Berard, BB-
033-00050) as well as several additional normal breast and tumor
tissue sections. H&E and IHC staining of paraffin sections of
normal human breast tissue and primary breast tumors was carried
out using standard methods and the following antibodies:
BMPR1B (ab78417) and BMP2 (ab6285; bothAbcam), and Pan-ker-
atin (clone AE1/AE3, 1/50, CC1 buffer), CD31 (clone JC70A, 1/50,
ICC1) and Pan-CD45 (clone 2B11+PD7/26, 1/20, ICC1) (all Dako)
and SMA (Roche Diagnostic, clone 1A4, 1/1) and CD10 (Novacas-
tra, Clone 56C6), Staining of 380 tumors of the TMAwas interpret-
able, and the statistical significance of staining was tested by
Monte Carlo simulation.number of luminal (Lu-ECP-DC), myoepithelial (Myo-ECP-DC), and
enitor content.
equency is shown ± SEM, n = 7.
wn (n = 3). UT, untreated; white area of chart, no E-CFC formation;
te myoepithelial, early/late luminal CFC (Mixed-CFC, Early Myo-CFC,
d in Figures S5B and S5C, ± SEM, n = 9.
n the presence of 50 ng/ml BMP2/4. The colony number is shown ±
P2/4. The colony number is shown ± SEM, n = 9, *p < 0.05. (B–D and
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Figure 7. BMP2, which Production Is
Induced by Carcinogens, Is Involved in
Regulation and Transformation of Human
Mammary Stem Cells
(A) ELISA quantification of BMP2 after
exposure of peripheral adipose tissue (n =
7), breast adipose tissue (n = 4), breast fi-
broblasts (n = 6), and stromal cells (n = 9) to
7 Gy irradiation, 107 M Bisphenol A/S
(BPA/BPS), 1010 M Benz(a)pyrene (BaP).
BMP2 levels are represented as ratios to
untreated control ± SEM.
(B and C) Induction of BMP2 expression
after 107 M BPA treatment of fibroblasts
from adipose or breast tissue from healthy
donors or breast cancer patients at least 1
year after treatment. Data represent the
percentage of patients showing an induc-
tion of BMP2 expression quantified by (B)
qPCR (healthy donor, n = 15; breast cancer
history, n = 10) or (C) ELISA (healthy donor,
n = 10; breast cancer history, n = 10).
(D) Proposed mechanism of BMP2 function.
In the normal breast, BMP2 commits com-
mon progenitors to the luminal lineage,
while BMP4 favors the maintenance of
immature cells and myoepithelial differen-
tiation. Exposure to environmental carcin-
ogens increases BMP2 levels. Intrinsic
alterations of luminal progenitors make the
cells susceptible to BMP2 and IL-6-depen-
dent changes of the microenvironment,
leading to full transformation. Ad, adipo-
cyte; Fb, fibroblast; SC, stem cell.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and five figures and can be found with this article on-
line at http://dx.doi.org/10.1016/j.stemcr.2014.12.007.
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